突变负担和抗PD-1结果并不总是与免疫细胞透或淋巴细胞激活有关

David Hsiehchen1, Andrew Elliott2, Joanne Xiu2

  • 1Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Cancer cell
|November 22, 2024
PubMed
概括

免疫细胞透和基因特征并不总是预测患者对抗癌症免疫疗法的反应,例如抗PD-1/L1治疗. 这些免疫学标记在各种癌症中不能可靠地表明瘤免疫性和治疗成功.